Drug Trial Radar · NCT01074944
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Last checked: Nov 19, 2026Latest source record: Feb 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Jun 2010
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).
Conditions
- Gaucher Disease
Interventions
Eliglustat tartrateDrug
Oral Capsule in 50 mg or 100 mg dosages
Primary outcomes
What the sponsor says the trial is designed to measure.
- PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAPTime frame: PAP Baseline up to the end of PAP (Week 52)
Locations
46 sites in 17 countries. Site status is shown where the registry gives one.
University of California, San Diego Medical Center
San Diego, California
Yale University School of Medicine
New Haven, Connecticut
Emory University Medical Center
Decatur, Georgia
Children's Memorial Hospital
Chicago, Illinois
Mount Sinai Medical Center
New York, New York
New York University School of Medicine
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
University of Utah
Salt Lake City, Utah
O and O Alpan LLC
Springfield, Virginia
Royal Prince Alfred Hospital
Camperdown, Australia
Monash Medical Centre
Clayton, VIC, Australia
Royal Perth Hospital
Perth, WA, Australia
Medical University Vienna
Vienna, Austria
Hospital das Clinicas da UFMG
Belo Horizonte, Brazil
Cettro - Centro de Tratamento de Oncologia e Hematologia
Brasília, Brazil
Hemocentro - UNICAMP
Campinas, Brazil
Instituto Tropical de Medicina Reprodutiva e Menopausa - INTRO
Cuiabá, Brazil
Hospital Universitario Walter Cantidio - HUWC
Fortaleza, Brazil
Hemocentro de Ribeirão Preto Núcleo de Hemoterapia de Franca
Franca, Brazil
Hemorio
Rio de Janeiro, Brazil
Hospital de Clínicas da Universidade Federal do Parana
São Paulo, Brazil
IGEIM - Institute of Genetic and Inborn Erros of Metabolism
São Paulo, Brazil
Mount Sinai Hospital
Toronto, Canada
Peking Union Medical College Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Shanghai Xinhua Hospital Shanghai Xinhua Hospital
Shanghai, China
Tianjin Hematonosis Hospital
Tianjin, China
University Hospital Centre Zagreb
Zagreb, Croatia
Hôpital Haut Lévêque
Bordeaux, France
Hôpital Femme Mère Enfant Centre de référence des maladies Héréditaires du métabolisme
Bron, France
General Hospital of Athens "G. Gennimatas"
Athens, Greece
King Edward Memorial (KEM) Hospital
Mumbai, India
Hiroshima University Hospital
Hiroshima, Japan
Jikei University Hospital
Tokyo, Japan
Juntendo University Hospital
Tokyo, Japan
Mie Chuou Medical Center
Tsu, Mie, Japan
Academic Medical Center
Amsterdam, Netherlands
Hospital de Santa Maria
Lisbon, Portugal
Hospital do Divíno Espírito Santo
Ponta Delgada - São Miguel - Açores, Portugal
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.